

REDACTION AND CONFIDENTIALITY LOG TO FORM HCMO-1 AND ATTACHMENTS

BATES REFERENCE	PARTY INFORMATION	INFORMATION REQUESTED	INFORMATION REDACTED	BASIS FOR REDACTION
HCMO_FORM_00000023 - HCMO_FORM_00000029	Dragonfly Health and Enclara Pharmacia	<u>Item 1; Item 2; Item 3; Item 7; Item 10(b); Item 10(c); Item 10(f)(vii); Item 10(f)(viii); Item 11(f)(vii); Item 11(f)(viii); Item 12; Item 13(b); Item 13(c); Item 13(f); Item 15(a); Item 15(b); Item 15(c); Item 16(a)</u>	HCMO-1 Confidential Appendix	<p>The Parties request confidential treatment of the information submitted in HCMO-1 Confidential Appendix. The non-public employee phone and email information, transaction negotiations; descriptions of governance structure, average daily census information, volume information, acquisition information, anticipated changes and impacts from the transaction contain confidential information about the Parties commercial operations, and non-public strategies, and disclosure of the additional details in the Confidential Appendix would cause commercial harm to the Parties. (See ORS 192.345(2)).</p> <p>Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing “all confidential information and documents that are not publicly available that are obtained in relation to a material change transaction”. As such, the Parties are requesting further confidential treatment of these materials.</p>
HCMO_ATT_00000208 – HCMO_ATT_00000478	Dragonfly Health	<u>Attachments to Section 7(b) of HCMO-1.</u>	Third-party due diligence reports	<p>Dragonfly Health requests confidential treatment of its third-party due diligence reports. These documents contain information about future strategic plans that is competitively sensitive, and disclosure would cause commercial harm to Dragonfly Health. (See ORS 192.345(2)).</p> <p>Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing “all confidential information and documents that are not publicly available that are obtained in relation to a material change transaction”. As such, Dragonfly Health is requesting further confidential treatment of these materials.</p>
HCMO_ATT_00002227 – HCMO_ATT_00002306	Dragonfly Health	<u>Financial Statements</u>	Audited Financial Statements of Dragonfly Health, Inc.	<p>Dragonfly Health requests confidential treatment of the Audited Financial Statements for Dragonfly Health. As a nonpublic entity, this information has not been made publicly available in any other forum. Further, this information is competitively sensitive, and disclosure would cause commercial harm to Dragonfly Health. (See ORS 192.345(2)).</p> <p>Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing “all confidential information and documents that are not publicly available that are obtained in relation</p>

BATES REFERENCE	PARTY INFORMATION	INFORMATION REQUESTED	INFORMATION REDACTED	BASIS FOR REDACTION
				to a material change transaction”. As such, Dragonfly Health is requesting further confidential treatment of these materials.
HCMO_ATT_00000479 – HCMO_ATT_00000967; HCMO_ATT_00002314 – HCMO_ATT_00002434	Dragonfly Health	<u>Governance Documents</u>	Non-public Governance documents for all Dragonfly Health entities	<p>Dragonfly Health requests confidential treatment of the non-public governance documents for Dragonfly Health entities (e.g., bylaws and LLC operating agreements). As a nonpublic entity, these documents have not been made publicly available in any other forum. Further, this information is competitively sensitive, and disclosure would cause commercial harm to Dragonfly Health. (See ORS 192.345(2)).</p> <p>Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing “all confidential information and documents that are not publicly available that are obtained in relation to a material change transaction”. As such, Dragonfly Health is requesting further confidential treatment of these materials.</p>
HCMO_ATT_00002307 – HCMO_ATT_00002310	Enclara Pharmacia	<u>Financial Statements</u>	Unaudited Financial Statements of Eagle Rx Holdco, Inc.	<p>Enclara requests confidential treatment of the unaudited financial statements for the business of Eagle Rx Holdco, Inc. These unaudited financial statements have not been made publicly available in any other forum. Further, this information is competitively sensitive, and disclosure would cause commercial harm to Enclara (See ORS 192.345(2)).</p> <p>Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing “all confidential information and documents that are not publicly available that are obtained in relation to a material change transaction”. As such, Enclara is requesting further confidential treatment of these materials.</p>
HCMO_ATT_00000968 – HCMO_ATT_00002223	Enclara Pharmacia	<u>Governance Documents</u>	Non-public governance documents for all Eagle Rx Holdco, Inc. entities	<p>Enclara requests confidential treatment of the non-public governance documents for all Eagle Rx Holdco, Inc. entities (e.g., bylaws and LLC operating agreements). These documents have not been made publicly available in any other forum. Further, this information is competitively sensitive, and disclosure would cause commercial harm to Enclara. (See ORS 192.345(2)).</p> <p>Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing “all confidential information and documents that are not publicly available that are obtained in relation to a material change transaction”. As such, Enclara is requesting further confidential treatment of these materials.</p>

BATES REFERENCE	PARTY INFORMATION	INFORMATION REQUESTED	INFORMATION REDACTED	BASIS FOR REDACTION
HCMO_ATT_00000001 – HCMO_ATT_00000207; HCMO_ATT_00002435 – HCMO_ATT_00002614	Dragonfly Health and Enclara Pharmacia	<u>Transaction Agreement</u>	Stock Purchase Agreement between StateServ Holdings LLC and Humana Inc. and Company Disclosure Schedules to the Stock Purchase Agreement between StateServ Holdings LLC and Humana Inc.	<p>The Parties request confidential treatment of the Stock Purchase Agreement and the Company Disclosure Schedules. The merger agreement and disclosure schedules have not been made public, and contain confidential information, and disclosure would cause commercial harm to the Parties. (See ORS 192.345(2)).</p> <p>Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing “all confidential information and documents that are not publicly available that are obtained in relation to a material change transaction”. As such, the Parties are requesting further confidential treatment of these materials.</p>
HCMO_ATT_00002615	Dragonfly Health	<u>Documentation or analytic support for response to Item 15(b)</u>	Internal Cost Savings Analysis.	<p>Dragonfly Health requests confidential treatment of the Internal Cost Savings Analysis. This document has not been made public, and contains confidential information, and disclosure would cause commercial harm to Dragonfly Health. (See ORS 192.345(2)).</p> <p>Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing “all confidential information and documents that are not publicly available that are obtained in relation to a material change transaction”. As such, Dragonfly Health is requesting further confidential treatment of these materials.</p>